Toll-like receptor-4 agonist inhibits motility and invasion of hepatoblastoma HepG2 cells in vitro

Pediatric Blood and Cancer

Volumn 60, Issue 2, 2013, Pages 248-253

  Hsiao, Chih Cheng ^a   Kao, Ying Hsien ^b   Huang, Shun Chen ^a   Chuang, Jiin Haur ^a  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^b I SHOU UNIVERSITY   (Taiwan)

Author keywords

Hepatoblastoma; IL 8; Lipopolysacharide; Matrix metalloproteinase 2; TNF ; Toll like receptor 4

Indexed keywords

ANTINEOPLASTIC AGENT; COLLAGENASE 3; CYTOKINE; GELATIN; GELATINASE A; INTERLEUKIN 8; MATRIGEL; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 4 AGONIST; TOLL LIKE RECEPTOR AGONIST; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; CANCER INVASION; CELL INVASION; CELL MOTILITY; CELL STRAIN HEPG2; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HEPATOBLASTOMA; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LIVER; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR GROWTH; WOUND HEALING; ZYMOGRAPHY;

EID: 84871161935     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.24211     Document Type: Article

References (42)

1. Kumagai Y, Takeuchi O, Akira S. Pathogen recognition by innate receptors. J Infect Chemother 2008; 14: 86-92.
2. Wang EL, Qian ZR, Nakasono M, et al. High expression of toll-like receptor 4/myeloid differentiation factor 88 signals correlates with poor prognosis in colorectal cancer. Br J Cancer 2010; 102: 908-915.
3. Yang H, Zhou H, Feng P, et al. Reduced expression of toll-like receptor 4 inhibits human breast cancer cells proliferation and inflammatory cytokines secretion. J Exp Clin Cancer Res 2010; 29: 92-99.
4. Zhang JJ, Wu HS, Wang L, et al. Expression and significance of TLR4 and HIF-1alpha in pancreatic ductal adenocarcinoma. World J Gastroenterol 2010; 16: 2881-2888.
5. Cherfils-Vicini J, Platonova S, Gillard M, et al. Triggering of TLR7 and TLR8 expressed by human lung cancer cells induces cell survival and chemoresistance. J Clin Invest 2010; 120: 1285-1297.
6. Goto Y, Arigami T, Kitago M, et al. Activation of toll-like receptors 2, 3 and 4 on human melanoma cells induces inflammatory factors. Mol Cancer Ther 2008; 7: 3642-3653.
7. Ilvesaro JM, Merrell MA, Swain TM, et al. Toll like receptor-9 agonists stimulate prostate cancer invasion in vitro. Prostate 2007; 67: 774-781.
8. Lee JW, Choi JJ, Seo ES, et al. Increased toll-like receptor 9 expression in cervical neoplasia. Mol Carcinog 2007; 46: 941-947.
9. Gatti G, Quintar AA, Andreani V, et al. Expression of toll-like receptor 4 in the prostate gland and its association with the severity of prostate cancer. Prostate 2009; 69: 1387-1397.
10. Merrell MA, Ilvesaro JM, Lehtonen N, et al. Toll-like receptor 9 agonists promote cellular invasion by increasing matrix metalloproteinase activity. Mol Cancer Res 2006; 4: 437-447.
11. Harmey JH, Bucana CD, Lu W, et al. Lipopolysaccharide-induced metastatic growth is associated with increased angiogenesis, vascular permeability and tumor cell invasion. Int J Cancer 2002; 101: 415-422.
12. Luo JL, Maeda S, Hsu LC, et al. Inhibition of NF-kappaB in cancer cells converts inflammation-induced tumor growth mediated by TNF-alpha to TRAIL-mediated tumor regression. Cancer Cell 2004; 6: 297-305.
13. Okamoto M, Oshikawa T, Tano T, et al. Involvement of toll-like receptor 4 signaling in interferon-gamma production and antitumor effect by streptococcal agent OK-432. J Natl Cancer Inst 2003; 95: 316-326.
14. Sfondrini L, Rossini A, Besusso D, et al. Antitumor activity of the TLR-5 ligand flagellin in mouse models of cancer. J Immunol 2006; 176: 6624-6630.
15. Berzsenyi MD, Roberts SK, Preiss S, et al. Hepatic TLR2 & TLR4 expression correlates with hepatic inflammation and TNF-alpha in HCV & HCV/HIV infection. J Viral Hepat 2011; 18: 852-860.
16. Sato K, Ishikawa T, Okumura A, et al. Expression of toll-like receptors in chronic hepatitis C virus infection. J Gastroenterol Hepatol 2007; 22: 1627-1632.
17. Riordan SM, Skinner NA, Kurtovic J, et al. Toll-like receptor expression in chronic hepatitis C: Correlation with pro-inflammatory cytokine levels and liver injury. Inflamm Res 2006; 55: 279-285.
18. Mozer-Lisewska I, Sluzewski W, Kaczmarek M, et al. Tissue localization of toll-like receptors in biopsy specimens of liver from children infected with hepatitis C virus. Scand J Immunol 2005; 62: 407-412.
19. Chew V, Tow C, Teo M, et al. Inflammatory tumour microenvironment is associated with superior survival in hepatocellular carcinoma patients. J Hepatol 2010; 52: 370-379.
20. Kuwada Y, Sasaki T, Morinaka K, et al. Potential involvement of IL-8 and its receptors in the invasiveness of pancreatic cancer cells. Int J Oncol 2003; 22: 765-771.
21. Luca M, Huang S, Gershenwald JE, et al. Expression of interleukin-8 by human melanoma cells up-regulates MMP-2 activity and increases tumor growth and metastasis. Am J Pathol 1997; 151: 1105-1113.
22. Waleh NS, Murphy BJ, Zaveri NT. Increase in tissue inhibitor of metalloproteinase-2 (TIMP-2) levels and inhibition of MMP-2 activity in a metastatic breast cancer cell line by an anti-invasive small molecule SR 13179. Cancer Lett 2010; 289: 111-118.
23. Giannelli G, Bergamini C, Marinosci F, et al. Clinical role of MMP-2/TIMP-2 imbalance in hepatocellular carcinoma. Int J Cancer 2002; 97: 425-431.
24. Mantovani A, Allavena P, Sica A, et al. Cancer-related inflammation. Nature 2008; 454: 436-444.
25. Wagenlehner FM, Elkahwaji JE, Algaba F, et al. The role of inflammation and infection in the pathogenesis of prostate carcinoma. BJU Int 2007; 100: 733-737.
26. Sato Y, Goto Y, Narita N, et al. Cancer cells expressing toll-like receptors and the tumor microenvironment. Cancer Microenviron 2009; 2: 205-214.
27. Molteni M, Marabella D, Orlandi C, et al. Melanoma cell lines are responsive in vitro to lipopolysaccharide and express TLR-4. Cancer Lett 2006; 235: 75-83.
28. Ren T, Wen ZK, Liu ZM, et al. Functional expression of TLR9 is associated to the metastatic potential of human lung cancer cell: Functional active role of TLR9 on tumor metastasis. Cancer Biol Ther 2007; 6: 1704-1709.
29. Fukata M, Chen A, Vamadevan AS, et al. Toll-like receptor-4 promotes the development of colitis-associated colorectal tumors. Gastroenterology 2007; 133: 1869-1881.
30. Kelly MG, Alvero AB, Chen R, et al. TLR-4 signaling promotes tumor growth and paclitaxel chemoresistance in ovarian cancer. Cancer Res 2006; 66: 3859-3868.
31. He W, Liu Q, Wang L, et al. TLR4 signaling promotes immune escape of human lung cancer cells by inducing immunosuppressive cytokines and apoptosis resistance. Mol Immunol 2007; 44: 2850-2859.
32. Waugh DJ, Wilson C. The interleukin-8 pathway in cancer. Clin Cancer Res 2008; 14: 6735-6741.
33. Naseemuddin M, Iqbal A, Nasti TH, et al. Cell mediated immune responses through TLR4 prevents DMBA-induced mammary carcinogenesis in mice. Int J Cancer 2012; 130: 765-774.
34. Tang XY, Zhu YQ, Wei B, et al. Expression and functional research of TLR4 in human colon carcinoma. Am J Med Sci 2010; 339: 319-326.
35. Szajnik M, Szczepanski MJ, Czystowska M, et al. TLR4 signaling induced by lipopolysaccharide or paclitaxel regulates tumor survival and chemoresistance in ovarian cancer. Oncogene 2009; 28: 4353-4363.
36. Garay RP, Viens P, Bauer J, et al. Cancer relapse under chemotherapy: Why TLR2/4 receptor agonists can help. Eur J Pharmacol 2007; 563: 1-17.
37. Krieg AM. Development of TLR9 agonists for cancer therapy. J Clin Invest 2007; 117: 1184-1194.
38. Drobits B, Holcmann M, Amberg N, et al. Imiquimod clears tumors in mice independent of adaptive immunity by converting pDCs into tumor-killing effector cells. J Clin Invest 2012; 122: 575-585.
39. Scheel B, Aulwurm S, Probst J, et al. Therapeutic anti-tumor immunity triggered by injections of immunostimulating single-stranded RNA. Eur J Immunol 2006; 36: 2807-2816.
40. Stockfleth E, Trefzer U, Garcia-Bartels C, et al. The use of toll-like receptor-7 agonist in the treatment of basal cell carcinoma: An overview. Br J Dermatol 2003; 149: 53-56.
41. Satoh M, Tsurumaki K, Kagehara H, et al. Induction of intratumoral tumor necrosis factor by a synthetic lipid A analog, ONO-4007 with less tolerance in repeated administration and its implication in potent antitumor effects with low toxicity. Cancer Immunol Immunother 2002; 50: 653-662.
42. Yan J, Wang ZY, Yang HZ, et al. Timing is critical for an effective anti-metastatic immunotherapy: The decisive role of IFNgamma/STAT1-mediated activation of autophagy. PLoS ONE 2011; 6: e24705- e24713.